Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 35, 2018 - Issue 7-8
Submit an article Journal homepage
266
Views
7
CrossRef citations to date
0
Altmetric
Report

Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction

Olive EcksteinTexas Children’s Cancer Center, Houston, Texas, USA;
,
Casey L. McAteeTexas Children’s Cancer Center, Houston, Texas, USA;
,
Jay GreenbergChildrens National Medical Center, Washington, District of Colombia, USA;
,
Ashish KumarCincinnati Children’s Medical Center, Cincinnati, Ohio, USA;
,
Carolyn Fein-LevyThe Steven and Alexandra Cohen Children’s Medical Center of New York, New York, USA;
,
Thomas SmithThe Children’s Hospital, Denver, Colorado, USA;
,
Brandon TranTexas Children’s Hospital Department of Radiology, Houston, Texas, USA
&
Kenneth L. McClainTexas Children’s Cancer Center, Houston, Texas, USA; Correspondence[email protected]
 show all
Pages 427-433 | Received 22 Aug 2018, Accepted 07 Nov 2018, Published online: 31 Dec 2018

References

  • Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881.
  • Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am. J. Neuroradiol. 2004;25(5):880–891.
  • Prosch H, Grois N, Wnorowski M, et al. Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. AJNR Am. J. Neuroradiol. 2007;28(6):1022–1028.
  • Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, et al. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur. Radiol. 2006;16(9):2074–2082.
  • Wnorowski M, Prosch H, Prayer D, et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J. Pediatr. 2008;153(1):127–132.
  • Japan LCH Study Group (JLSG), Imashuku S, Fujita N, Shioda Y, et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int. J. Hematol. 2015;101(2):191–197.
  • Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr. Blood Cancer. 2010;54(3):416–423.
  • Euskirchen P, Haroche J, Emile J-F, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol. Neuroimmunol. Neuroinflamm. 2015;2(2):e78.
  • Donadieu J, Armari-Alla C, Templier I, et al. First use of vemurafenib in children LCH with neurodegenerative LCH. Pediatr. Blood Cancer 2015;62:S7.
  • McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 2018;124:2607–2620.
  • Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343–369.
  • Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 2015;15(9):545–558.
  • Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr. Opin. Neurol. 2015;28(3):237–243.
  • Szalardy L, Zadori D, Simu M, et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J. Neurol. Sci. 2013;331(1–2):38–42.
  • Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010;74(23):1860–1867.
  • Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–123.
  • Deligne C, Metidji A, Fridman W-H, Teillaud J-L. Anti-CD20 therapy induces a memory Th1 response through the IFN-gamma/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia. 2015;29(4):947–957.
  • Ireland S, Monson N. Potential impact of B cells on T cell function in multiple sclerosis. Mult. Scler. Int. 2011;2011(3):423971–423979.
  • Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 1997;145(2):205–211.
  • Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr. Blood Cancer. 2018;65(1):e26784–e26710.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.